Kuros Biosciences (KURN) Q1 2026 TU earnings summary

Executive summary

• Achieved 51% year-over-year sales growth in Q1 2026, reaching USD 43.4 million in product sales.

• Strong commercial execution in minimally invasive surgery (MIS) and extremities segments, with broader adoption of Magnetos products.

• U.S. headquarters and manufacturing facility in Georgia on track for H2 2026 production; Netherlands facility expansion progressing.

Financial highlights

• Total product sales rose to USD 43.4 million, up from USD 28.8 million in Q1 2025.

• Direct Magnetos product sales increased to USD 42.9 million, up from USD 28.4 million year-over-year.

• Group EBITDA reached USD 2.9 million, up from USD 2.0 million in Q1 2025.

• Adjusted EBITDA was USD 5.7 million (13.1% margin), compared to USD 3.3 million (11.6% margin) in Q1 2025.

• Cash and cash equivalents stood at USD 15.7 million, down from USD 19.8 million at year-end 2025 due to investments in production capacity.

Outlook and guidance

• Confident acceleration into Q2 2026, supported by strong demand across spine and extremities businesses.

• Manufacturing expansion expected to reduce supply chain risk and support long-term revenue growth.